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Abstract
Cyclopia is characterized by the presence of a single eye, with varying degrees of doubling of the 
intrinsic ocular structures, located in the middle of the face. It is the severest facial expression of 
the holoprosencephaly (HPE) spectrum. This study describes the prevalence, associated 
malformations, and maternal characteristics among cases with cyclopia. Data originated in 20 
Clearinghouse (ICBDSR) affiliated birth defect surveillance systems, reported according to a 
single pre-established protocol. A total of 257 infants with cyclopia were identified. Overall 
prevalence was 1 in 100,000 births (95%CI: 0.89–1.14), with only one program being out of 
range. Across sites, there was no correlation between cyclopia prevalence and number of births (r 
= 0.08; P=0.75) or proportion of elective termination of pregnancy (r= −0.01; P=0.97). The higher 
prevalence of cyclopia among older mothers (older than 34) was not statistically significant. The 
majority of cases were liveborn (122/200; 61%) and females predominated (male/total: 42%). A 
substantial proportion of cyclopias (31%) were caused by chromosomal anomalies, mainly 
trisomy 13. Another 31% of the cases of cyclopias were associated with defects not typically 
related to HPE, with more hydrocephalus, heterotaxia defects, neural tube defects, and preaxial 
reduction defects than the chromosomal group, suggesting the presence of ciliopathies or other 
unrecognized syndromes. Cyclopia is a very rare defect without much variability in prevalence by 
geographic location. The heterogeneous etiology with a high prevalence of chromosomal 
abnormalities, and female predominance in HPE, were confirmed, but no effect of increased 
maternal age or association with twinning was observed.
Keywords
cyclopia; holoprosencephaly; trisomy 13; prevalence; global; world prevalence; epidemiology; 
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INTRODUCTION
“Cyclopia is a congenital malformation characterized by the presence of a single 
eye, which usually manifests various degrees of doubling of intrinsic structures, 
located in the middle of the face in the place normally occupied by the root of the 
nose.”
With this elegant definition Sedano and Gorlin began their 1963 article about the oral 
manifestation of cyclopia, reporting two cyclopia patients and a literature review about the 
specific manifestations of cyclopia that deserves an actual reading because of its 
completeness. Holoprosencephaly (HPE) was also reviewed in extenso in a special issue of 
Orioli et al. Page 2
Am J Med Genet C Semin Med Genet. Author manuscript; available in PMC 2015 June 29.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Part C in the American Journal of Medical Genetics[Muenke et al., 2010]. Thus only new 
pertinent information will be included here.
Usually considered as the severest gradation of facial malformation associated with HPE, 
cyclopia rarely is presented separately from other HPE types. Cyclopia by itself appeared in 
the epidemiological work of Källén et al. [1992], in the chapter in a more general work 
about HPE [Cohen and Sulik, 1992], and among few median anomalies in the interpretative 
work of O’Railly and Muüller [1989]. However, there are hundreds of case reports of 
cyclopia in humans and in other vertebrates, besides the experimental studies in animal 
models causing cyclopia. This vast amount of case reports in the literature on cyclopia 
allows us to have an exact idea about the phenotypic variation and possible etiologies of this 
condition. The rarity of the condition, however, does not allow epidemiological studies to 
demonstrate the risk factors and the contribution of each one to the onset of cyclopia. Using 
material registered by the Clearinghouse [ICBDSR, 2009] from millions of births surveyed 
by 20 surveillance programs worldwide, our aim here is to analyze the prevalence and 
possible risk factors of cyclopia.
Historical Aspects
Recent reviews of teratology and mythology by Cohen [2010b], and by Stahl and Tourame 
[2010] agreed with previous reviewers that real newborns with those defects existed in the 
origin of the mythological creatures and fantastic beings. Although there is no way to be 
sure of the population number at the year 800 BC in all the world, an educated guess 
suggested 66,000,000[Mc Evedy and Jones, 1978], and another guess suggested a crude 
birth rate of 80 per 1,000 for this period (http://www.prb.org/Articles/2002/
HowManyPeopleHaveEverLivedonEarth.aspx)opia w. If so, around the time Odyssey was 
being composed, approximately 53 cases of cyclopia were born by year, in the world 
population. We can speculate on how this small number of cases could have caused such an 
impressive impact on the people’s imagination. One possibility is that in those earlier times, 
the prevalence of cyclopia was higher than it is now. There are many other possibilities as 
there are scholarly theories of the myths. The study of the origin of the myths probably 
requires tools from other fields such as anthropology, psychology, sociology, or semiology.
Normal and Abnormal Development
As part of the HPE spectrum, the prosencephalon in cyclopia cases fails to develop into two 
hemispheres [Cohen and Sulik, 1992]. Although HPE is usually divided into alobar, 
semilobar, and lobar types according to severity, to the presence or not of the 
interhemispheric fissure and the extent of separation of both hemispheres [DeMyer and 
Zeman, 1963], cyclopia presents almost always as the alobar type. Only few instances of 
semilobar HPE were found in the literature [Orioli and Castilla, 2007; Dane et al., 2009]. In 
the alobar type there is complete or near complete lack of interhemispheric separation, 
single midline forebrain ventricle, absent interhemispheric fissure, falx cerebri, olfactory 
bulbs, and corpus callosum; and nonseparation of deep gray nuclei, as summarized in the 
HPE flashcards produced by Solomon et al. [2010]. Also published were detailed aspects on 
early pathogenesis [Shiota and Yamada, 2010], neuropathology [Hahn and Barnes, 2010], 
and neuroimaging [Marcorelles and Laquerriere, 2010].
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In 1963, Sedano and Gorlin presented the discussion between two apparently conflicting 
theories, among others, to explain the pathogenesis of cyclopia. In one theory the condition 
is said to be caused by abnormal differentiation of the prochordal mesoderm in the central 
part of the developing head region. Another hypothesis states that the brain malformation is 
the primary anomaly. Today, it is clear that both are involved but one of the key signaling 
centers for the pathogenesis of HPE is the most anterior extent of the midline mesoderm, 
called the prechordal plate. Several signals emanate from the prechordal plate and trigger a 
secondary patterning center in the ventral forebrain. Two complete reviews [Klingensmith et 
al., 2010; Roessler and Muenke, 2010] show that the requirement for delicate balancing of 
numerous key influences includes hedgehogs, fibroblast growth factors (Fgfs), bone 
morphogenic proteins (Bmps), retinoic acid, and canonical and noncanonical Wnt signaling.
England et al. [2006] labeled every cell nuclei of zebra-fish embryos with green fluorescent 
protein to visualize and track their movements and produced a dynamic fate map of the 
forebrain showing how the vertebrate eyes form. The authors also tested zebrafish embryos 
with two different mutations causing cyclopia showing that cyclopia in Cyclops (loss of 
Ndr2) results in corporation of eye tissue into an inappropriate location within the medial 
neural keel (an intermediate stage between the neural plate and neural rod during the early 
segmentation period in the morphogenesis of the central nervous system primordium); the 
much reduced convergent and forward movement of lateral-posterior eye-field cells fated to 
the optic stalk in Silberblick cyclopia mutants (loss of Wnt11) results in medial-posterior 
eye-field cells remaining medial. These two defects of forebrain morphogenesis are 
temporally and spatially distinct pointing to the recognized etiologic heterogeneity of 
cyclopia.
Genetics and Clinical Genetics
Cyclopia is an etiologically heterogeneous condition, which can result from chromosomal 
defects, genetic mutations, or environmental teratogenic factors. Several important reviews 
address the HPE etiology, mostly by M Michael Cohen Jr., but also by Maximilian Muenke, 
and by Sylvie Odent and Veronique David groups. In general there is little information 
about the etiology of cyclopia specifically in those reviews because cyclopia is considered to 
be the severest form of HPE [Cohen, 1989a; Muenke and Beachy, 2000; Dubourg et al., 
2007].
Trisomy 13 is the most common chromosomal disorder associated with HPE. The trisomies 
18 and 21 have also been described, as well as triploidy. The structural abnormalities 
described in the literature on 11 different chromosomes allowed the identification of 12 loci 
for HPE [Roessler and Muenke, 1998]. These loci are called HPE1 to HPE12 and are 
located in regions 21q33.3, 2p21 (SIX3), 7q36 (SHH), 18p11.3 (TGIF), 13q32 (ZIC2), 
2q371–q37.3, 9q22.3 (PTCH1), prox 14q, 20p13, 1q42-qter (DISP1), 5pter, and 6q26-qter 
[Dubourg et al., 2007]. Only six genes (in parentheses) were assigned to the loci HPE2, 
HPE3, HPE4, HPE5, HPE7, and HPE10. There are no genes reported yet for the other six 
loci. Cohen [2006, 2010a] presented complete reviews including other genes associated with 
HPE; however, only the Smith–Lemli–Opitz syndrome gene, DHCR7 on 11q12–q13, was, 
in the literature, associated with cyclopia in one case.
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Point mutations are found in syndromes presenting HPE. The OMIM database (http://
www.ncbi.nlm.nih.-gov/omim/), visited on March 30th, 2011) presented 31 syndromes 
showing HPE (Table I). A careful review of them shows that only four, the dysgnathia 
complex (or agnathia–HPE or otocephaly) (OMIM 202650), the Pseudotrisomy 13 
syndrome (OMIM 264480), the Steinfeld syndrome (OMIM 184705); and the Smith–Lemli–
Opitz syndrome (OMIM 270400), had cyclopia [Atkin, 1988; Cohen and Gorlin, 1991; 
Nöthen et al., 1993; Rolland et al., 1991; Weaver et al., 2010]. Also, only these four 
syndromes plus osteopathia striata with cranial sclerosis (OMIM 300373) presented with the 
alobar type of HPE. There are descriptions of other syndromes presenting HPE in the 
literature, as Rubinstein–Taybi syndrome, Meckel syndrome [Hsia et al., 1971], and Martin 
syndrome [Martin et al., 1977], not disclosed in Table I, since they are not associated with 
HPE in the OMIM database (Table I).
Some cyclopia patients present with one or more unrelated congenital anomalies that are not 
part of the non-chromosomal syndromes cited above. Concurrence of cyclopia and 
sirenomelia in the same patient was reported by Martínez-Frías et al. [1998], while 
associations of both defects with similar epidemiological risk factors were found by Källén 
et al. [1992]; involvement in the same clusters was reported by Castilla et al. [2008], and 
sharing of a similar pathogenetic mechanism was noted by O’Railly and Mu¨ller [1989].
Classification and Nomenclature
A classical paper, whose title humorously and intelligently, two conditions rarely found in 
medical literature, proposed that “The face predicts the brain” was published by DeMyer et 
al. [1964]. However, as science has no room for poetic licenses, this publication was 
criticized based on reported patients which did not fit into this axiom [Olsen et al., 1997; 
Plawner et al., 2002], while Cohen [1989b] quantified the exceptions to the rule, concluding 
that the proportion of patients where the face did not predict the brain comprised from 10 to 
39% of all HPE patients [Levey et al., 2010].
From the anatomo-pathological point of view, three types of HPE were described by 
DeMyer and Zeman [1963], in decreasing severity: alobar, semilobar, and lobar; while 
clinically the following types were proposed with certain degree of correspondence with the 
brain anatomy [DeMyer et al., 1963]: (1) Medial monophtalmia with arrhinia and proboscis 
(cyclopia), (2) ethmocephaly with supra-orbital proboscis, (3) hypotelorism, inter- or infra-
orbital proboscis with single nostril (cebocephaly), (4) median cleft of the upper lip with 
agenesis of premaxilla (with HPE obviously).
Proboscis refers to a blind-ending tube-like structure at or near the midline of the face, and 
can be supra or infra orbital, synophthalmia refers to merged ocular globes with variable 
degrees of fused ocular structures. Synophtalmia is sometimes used as cyclopia synonym as 
pointed out by Cohen and Sulik [1992] or to mean fused eyes in one orbit, as used by 
Solomon et al. [2010]. Since this is not a real fusion but rather a defect in the patterning of 
the eye fields, synophtalmia could be a misleading term. The origin of the word cyclopia is 
also controversial and it might not even mean one-eyed people.
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Cyclopia represents between 10% [Orioli and Castilla, 2007] and 20% [Mastroiacovo et al., 
1992] of all HPE as reported by the two largest published series, the difference being 
probably due to variation in phenotypic documentation.
Epidemiology (Includes Prevalence, and Risk Factors, Known or Hypothetical)
In a recent review of HPE epidemiology [Orioli and Castilla, 2010], that included 
prevalence and risk factors, 24 HPE published series around the world were reviewed. Two 
years before, HPE data from 24 of the 46 Birth Defects Registry Members of the 
International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR)
[Leoncini et al., 2008] were also analyzed. Thirteen members of the ICBDSR also 
participated in the unique epidemiology study dealing only with cyclopias [Källén et al., 
1992]. From these three studies, we concluded that there are several factors to explain the 
observed epidemiologic differences in maternal age, twinning rate and sex among the 
studied populations. Operational factors as the different proportions of embryos, fetuses, 
still-borns, and liveborns in each studied population will result in different proportions of 
HPE caused by chromosomal abnormalities. The younger the patients the higher the 
prevalence of chromosomal abnormalities. Then, variables such as maternal age and other 
associated with it will change accordingly.
In regard to specific environmental risk factors, Cohen and Shiota [2002] reviewed several 
factors, including ethyl alcohol, diabetic embryopathy, retinoic acid, and several anecdotal 
suggestions of teratogenic factors for HPE, including viruses, and salicylates. Orioli and 
Castilla [2007] confirmed in a South American series maternal diabetes and maternal flu as 
more prevalent in HPE than in controls. Miller et al. [2010] analyzed case patients and 
controls from the National Birth Defects Prevention Study and found HPE to be associated 
with pre-existing diabetes, aspirin use, lower education level, and use of assisted 
reproductive technologies. In the same issue, Johnson and Rasmussen [2010] provided a 
summary of nongenetic risk factors for HPE that have been investigated in case reports and 
case series, animal studies, and epidemiologic studies, including maternal illnesses, 
therapeutic and nontherapeutic exposures, nutritional factors, and sociodemographic factors.
METHODS
Birth defects surveillance programs that are part of ICBDSR were asked to provide de-
identified case records following a common protocol, with information on phenotype, 
genetic testing, and selected demographic and prenatal information. Further details on the 
methodologies can be found in Castilla and Mastroiacovo [2011] in this issue. As part of the 
Very Rare Defect study of the ICBDSR, 20 surveillance programs in 25 countries (10 
countries represented in Estudo Colaborativo Latino Americano de Malformações 
Congênitas: ECLAMC), from North and South America, Europe, Israel, China and Australia 
provided data on cyclopia from an underlying cohort of 25.6 million births. The years 
represented were 1968–2006, depending on the reporting site.
Clinical and demographic data were reviewed centrally by two authors with experience in 
dysmorphology (IO and PM). Additional information for inclusion or exclusion of cases was 
also requested in a second step by one author (IO). After the identification of all 
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chromosomal and nonchromosomal syndromes, the remaining cases with multiple 
congenital anomalies (MCA) were classified according to the number of unrelated defects to 
the HPE spectrum [Orioli and Castilla, 2007], and according to the presence of postaxial 
polydactyly All cases were reported by verbatim description, and centrally classified without 
coding. Nevertheless in 222 of the 257 patients (86%), the defect was reported by a single 
word (i.e., cyclopia), therefore consisting of just a naming rather than of a real description. 
In 35 cases more details were provided on the HPE type, and/or the presence of proboscis, 
and/or the number of eyes inside the orbit.
Occurrence was expressed as total prevalence [number of live births, stillbirths and elective 
termination of pregnancy for fetal anomaly (ETOPFA) with cyclopia per 100,000 births] 
with its 95% confidence intervals (CI). For each program the expected number of cases was 
calculated under the hypothesis of a homogeneous prevalence among all programs. Using 
the expected values we calculated the exact Poisson probabilities of observing N or more 
cases [P(N ≥ x)] in each registry. Maternal age-specific prevalence ratios were calculated 
across several clinical subtypes (isolated, MCA, and chromosomal syndromes) with women 
<20 years of age serving as the referent group. Odds ratios and 95%CI were computed 
across clinical subtypes to examine the association of various characteristics using both 
isolated and MCA as a referent group. Pearson correlation was used as a measure of 
correlation between the prevalence of cyclopia and two variables: the number of births and 
the proportion of ETOPFA in each registry.The 95% CI were computed using the Poisson 
distribution. Statistical tests significance was set to P < 0.05. Statistical analyses were done 
with Stata software, version 10.0 [StataCorp., 2007].
RESULTS
Prevalence
The total number of births and of cyclopia cases is given in Table II for each one of the 20 
surveillance programs members of the ICBDSR. A total of257 infants with cyclopia were 
identified among 25,580,661 births, giving a total prevalence of 1.0 per 100,000 births 
(95%CI: 0.89–1.14).
About half (54.0%) of the cases with cyclopia in this study were provided by four reporting 
surveillance programs: South America ECLAMC, France Central East, China Beijing, and 
USA Texas.
ETOPFA is not permitted for two surveillance programs (Mexico RYVEMCE: Registro y 
Vigilancia Epidemiológica de Malformaciones Congénitas, and South America ECLAMC). 
Furthermore, it was not recorded in two other surveillance programs (Spain ECEMC: 
Spanish Collaborative Study of Congenital Malformations, and China, Beijing), and was 
recorded at an unknown and probably variable ascertainment rate in the rest.
Figure 1 compares estimates of the cyclopia prevalences with their 95%CI among the 
different surveillance programs. Only Hungary’s prevalence’s upper confidence limit was 
below the total prevalence of 1.0 per 100,000 births suggesting under-registration (0,26 per 
100,000; CI: 0.11–0.52, P< 0.0001). Excluding this program, the overall prevalence of 1.10 
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per 100,000 is estimated for all the remaining programs, with a marginal statistically 
significant higher prevalence estimated in Italy North-East (1.77, CI: 1.10–2.71). There was 
no correlation between the cyclopia prevalence and number of births (r = 0.08; P=0.75) or 
proportion of elective termination of pregnancy (r=−0.01; P=0.97) in each surveillance 
program.
Secular Variation and Clustering of Cases
The rarity of cyclopia induces great variation in the annual frequencies within each one of 
the 20 programs without evident secular trends in any program. None of the programs 
reported an evidence of a cluster of cases.
Maternal Age
Maternal age was not specified in 9.8% of the total births and in 18.4% of the cases with 
cyclopia. Maternal age was analyzed by 5-year groups in 19 programs by clinical 
phenotypes: isolated, MCA, and chromosomal abnormalities. Figure 2 shows that cases with 
chromosomal abnormalities presented a statistically significant increasing trend (P=0.015), 
as expected. The MCA case group did not show any maternal age trend, but the oldest 
mothers (>40 years of age) had a prevalence that was over four times the prevalence among 
the referent group of youngest mothers (<20 years of age) (prevalence ratio 4.33, 95%CI: 
1.16–16.12). Isolated cases did not present any maternal age effect, These results suggest 
that a number of undiagnosed cases of chromosomal trisomies could be present within the 
MCA group, but not within the isolated group.
Cases’ Characteristics by Clinical Phenotype
Chromosomal syndromes—There were 79 cases with chromosomal syndromes, 
accounting for 31% of the cyclopias. Only 23% of total cases had an available karyotype, 
since karyotyping was not done or reported in all cases. Given the limited reporting on 
karyotypes, it is possible that the estimate of chromosomal syndromes may be higher than 
the 31% referred here. For example, two South American associated cases left out from the 
chromosomal syndromic group in the material presented here, were later on proved to have a 
chromosomal anomaly by multiplex ligation-dependent probe amplification (MLPA) 
analysis. Most of these 81 cases (79 + 2) were trisomy 13 (n = 68; 84%), followed by 
trisomy 18 (n = 6)or partial shortarm monosomy (n=3) (subtotal n=9; 10%). In addition 
there were two cases with triploidy, one with trisomy 21, and one with a partial deletion of 
7q36.
The main characteristics of chromosomal syndromes are shown in Table III. The proportion 
of males (0.47) did not differ from the expected in the 78 specified cases. More than half of 
cases are stillborn or submitted to ETOPFA, and almost 80% have low birth weight.
The comparison of the characteristics of chromosomal syndrome cases versus isolated and 
MCA cases are shown in Table IV, where the odds ratios of the possible “risk factors” 
(characteristics) with their 95%CI were computed using both isolated and MCA as a referent 
group. In this analysis only programs with less than 20% of unknown information were 
used. The occurrence of an elective termination (or ETOPFA) was approximately 3.5 times 
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more likely among chromosomal cases than isolated cases (OR = 3.48, 95%CI: 1.53–7.90). 
No significant associations were found when chromosomal cases were compared with MCA 
cases.
Multiple congenital anomalies (MCA)—There were 81 cyclopia cases (31%) with 
associated defects not usually considered as part of the HPE spectrum. As mentioned before, 
we expected that with all cases fully analyzed for chromosomal abnormalities this 
proportion could be lower. When grouping these cases according the number of non-related 
HPE defects, 45 had only one associated defect (55%), 19 had two (24%), and 17 (21%) had 
three, four, or five associated defects. Most of these associated defects were similar to the 
ones found in the chromosomal syndromes, mainly omphalocele, anal atresia, cardiac, renal, 
and postaxial polydactyly. Postaxial polydactyly was present in 22/81 (27%) of the MCA 
cases. Different from the chromosomal syndromes, this group presented more cases with 
heterotaxia defects (6/81), neural tube defects (10/81), and preaxial limb reduction defects 
(9/81). Few nonchromosomal syndromes or associations could be suspected among the 
MCA cases: there were two cases with otocephaly—HPE, and two less typical examples of 
the dysgnathia complex, one case of prune belly, one case of VATER association with 
hydrocephalus, one chondrodystrophy not further specified, and one case of cyclopia and 
sirenomelia in the same case. This last case, according to the partial description, probably 
was a case with cyclopia, sirenomelia, and acardia-acephaly. The defects presented by some 
of these cases are displayed in Box I.
The main characteristics of the MCA cases are shown in Table III. The proportion of male 
(M/T = 0.41) observed did not differ from the expected. More than half of cases were 
stillborn or submitted to ETOPFA.
Comparing these characteristics with the isolated cases (the comparison with chromosomal 
syndromes is given above) revealed only one marginal statistical association with ETOPFA 
(OR= 2.52; 95%CI: 1.07–5.94).
Isolated cases—The main characteristics of isolated cases are shown in Table III. The 
proportion of males (0.38) was statistically significant different from the expected (χ2 = 
6.53; P < 0.05). More than half of cases were liveborn, and more than 50% have low birth 
weight.
DISCUSSION
Prevalence
The cyclopia prevalence 1.0 per 100,000 births (CI: 0.89–1.14) found in over 25 million 
births did not differ from 1.03 found previously by Källén et al. (1992) Although both series 
of data came from the Clearinghouse, there were data overlapping only for the Mexican, 
South American, Spanish, and French registries. The other 16 registries did not participate in 
the former work(Källén et al., 1992).
Cyclopia has been reported as between 10% and 18% of the HPE published series, as 
revised by Orioli and Castilla, (2010). There are two epidemiology works about HPE using 
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the Kyoto Collection of Embryos [Matsunaga and Shiota, 1977; Yamada et al., 2004], 
however only 11 embryos at Carnegie stage 8–21 had facial anomalies described in the last 
work. Two embryos presented complete cyclopia and three presented partially fused eyes in 
a single eye fissure, elevating the proportion of cyclopias among HPE to 45% in embryos.
Few studies report on the proportion of cyclopias or HPE among trisomy 13 patients. Källén 
et al. [1992] found 8 cyclopias in 436 (1.8%), and Wyllie et al. [1994] found one HPE 
among 36 trisomy 13 patients (2.8%). Considering a recent estimate of trisomy 13 
prevalence of 0.14/1,000 (0.12–0.17) [Irving et al., 2011] we would have expected 3,581 
patients of trisomy 13 among the 25,580,661 births, and also expected 99 cyclopias with 
trisomy 13. However, we detected only 68 cyclopia cases (69%) with trisomy 13.
Clustering of Cases
None of the reporting programs, including South America, reported evidence of a cluster of 
cases. A significant cluster of sirenomelia and cyclopia in the city of Cali, Colombia 
[Castilla et al., 2008], was not reflected in the South American material presented in this 
present work since the four cases of cyclopia born in Cali in 2005 were diluted when merged 
together with another 243 cases from other South American cities and periods. This 
exemplifies well the need for active ongoing surveillance of the collected data, which 
allowed the ECLAMC program to detect the cluster within a few weeks after the fourth case 
of this epidemic was born. When active surveillance is routinely working, the cluster is first 
suspected as a rumor that arises by an “alert practitioner” who was part of an epidemiology 
system, capable of following up on the rumor.
Maternal Age
As an important proportion of cyclopias (29%) are associated with trisomy, with an 
expected increased maternal age among deliveries, we expected a higher proportion of older 
age mothers among the cyclopia patients. However, the increased rate of cyclopias seen in 
the older maternal age groups (above 29 years old) in the total sample was not statistically 
significant. Only mothers 40 years old or above in the MCA group were in excess with 
respect to the mothers in the range <20. This suggests two possible explanations: (1) there is 
a substantial number of trisomy cases under-diagnosed among the MCA nonchromosomal 
group; and (2) a maternal age effect in trisomy 13 is not as important as the maternal age 
effect reported in other trisomies, as trisomy 18, for example [Crider et al., 2008].
Twinning
Only 6 from 231 infants with cyclopia were twins (2.6%). This low frequency of twinning 
differs from the excess of twinning reported by Källén et al. [1992]. The greater size of the 
present sample (25.6 million births) compared with the sample size used by Källén et al. 
[1992] (10.1 million births) could be an explanation.
Sex
Mastroiacovo et al. [1992], Rasmussen et al. [1996], and Orioli and Castilla [2010] did not 
confirm the excess of females among HPE patients as described in other series. The excess 
of female patients among cyclopias as seen in our work among the isolated cases or in 
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Källén et al. [1992], or in other previous HPE series [Roach et al., 1975; Croen et al., 1996, 
2000; Forrester and Merz, 2000; Chen et al., 2005] could be attributed to the excess loss of 
male embryos through spontaneous abortion [Rasmussen et al., 1996]. This idea was 
founded on studies of HPE in embryos [Matsunaga and Shiota, 1977], who showed a much 
higher rate of HPE than in newborns, and also on studies of fetuses with HPE, where an 
equal sex ratio or even a male excess could be observed [Blaas et al., 2002]. The lack of sex 
difference in the MCA, chromosomal syndromes and ETOPFA samples in the present work 
is consistent with this hypothesis, as well as the already mentioned presence of undetected 
chromosome syndrome patients in the MCA group.
Nonchromosomal Syndromes or Associations
In Table I are presented 31 syndromes that, with three possible exceptions, are 
nonchromosomal syndromes. The exceptions are pseudo-trisomy 13 (HPE-polydactyly), 
Currarino syndrome, and Jacobsen syndrome that could be caused by microdeletions on 
chromosome 13, 7q36, and 11q chromosomal regions, respectively. We scrutinized the 81 
patients in the MCA group looking for examples of these syndromes without much exit. 
Several cases could be suspected of trisomy 13 or of pseudo-trisomy 13, mainly those with 
postaxial polydactyly. Few were suspected of other nonchromosomal syndromes has can be 
viewed in Box I.
It is out of the scope of this work to confirm the suggested diagnoses in Box I. However, the 
two otocephaly or agnathia-HPE patients have clear diagnoses. A recent otocephaly review 
[Faye-Petersen et al., 2006] shows an otocephaly prevalence around 1:70,000 births and 
reported that half of them present HPE. Since a conservative estimate of cyclopia among 
HPE is 10%, we must expect 18 patients with cyclopia-otocephaly association in our 
material {[(25,580,661/70,000)/2)/0.10}. The poor description observed in 86% of our cases 
with cyclopia could explain why we identify only 10% of the expected number of this 
association.
There is another possible reason to explain the few examples of syndromes we found in our 
MCA material. A careful review of the type of HPE associated with each one of those 31 
syndromes in Table I shows that only the first four were ever associated with alobar HPE 
and with cyclopia: dysgnathia complex (OMIM 202650), pseu-do-trisomy 13 (OMIM 
264480), Steinfeld syndrome (OMIM 184705), and Smith–Lemli–Opitz syndrome (OMIM 
276400).
The interesting case with cyclopia, sirenomelia, and acardia-acephaly was not found 
previously described in the literature. However, several patients reviewed by Siebert [2007] 
presented cerebral defects as cyclopia, aprosencephaly, or atelencephaly with acardiac 
twinning. Hypoxia-ischemia due to twin reversed arterial perfusion (TRAP) is a common 
explanation for these defects and probably can explain the presence of sirenomelia in our 
present case. Acardia-acephaly with sirenomelia is also a combination of two very rare 
defects already published [Martínez-Frías, 2009; Orioli et al., 2011, this issue).
Ultimately, a new type of pathogenesis, the ciliopathies, have been proposed to explain a 
large number of diseases, mainly heterotaxia defects, hydrocephaly, neural tube defects, and 
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other defects related to twining [Hildebrandt et al., 2011]. Six patients within the MCA 
group of cyclopias presented with these kind of heterotaxic defects as accessory spleen, situs 
inversus, situs ambiguous, and lung isomerism; 6 presented with hydrocephalus, and 10 
presented with NTD. With the exception of hydrocephalus, these defects were not found in 
excess among a South American HPE series [Orioli and Castilla, 2007]. We cannot test the 
statistical significance of this excess in our cyclopia sample; however, only 2 cases with 
bilobar lung, and no cases with hydrocephalus or NTD occurred in the chromosomal 
anomaly group of 79 patients. Also, only one patient with preaxial reduction defect was seen 
in the chromosomal group. There are several phenotypes associated with cilia dysfunction in 
mammals including randomization of the left–right body axis, abnormalities in neural tube 
closure and patterning, skeletal defects such as poly-dactyly, etc. A new locus for Meckel 
syndrome (MK8), a diagnosis that can be confounded with trisomy 13, was described 
[Shaheen et al., 2011], and map to TCTN2 a paralog for Tectonic 1, which was involved in 
Sonic Hedgehog (SHH) signaling. SHH has been described as one of the most important 
genes causing HPE what reinforces the possible causal role of ciliopathies in the cyclopia 
causation.
Are Cyclopias Different From HPE?
Since cyclopias are rare, there are difficulties in collecting enough patients to compare 
epidemiologically with HPE in general. In this work a sample of 257 cyclopias could be 
analyzed and no important differences were demonstrated with respect to HPE 
[Mastroiacovo et al., 1992; Orioli and Castilla, 2007; Orioli and Castilla, 2010]. Although 
the analyses of environmental factors was limited by missing data, the available data show 
one patient of mother with diabetes, no patients of alcoholic mothers, two patients born after 
threatened abortion, one using misoprostol and one not further specified, and a half dozen 
patients born after maternal flu or fever, among a few other gestational exposures. In 
general, these limited findings agree with previous HPE epidemiological data reviewed by 
Orioli and Castilla [2010]. There are several possible causes of HPE, but we could not 
highlight any of them as more important or more specific to cause cyclopia. Only the pattern 
of associated defects in the group MCA seems to indicate a possible role of ciliopathy 
disorders to explain some cases of cyclopia.
CONCLUSION
The cyclopia prevalence of 1 per 100,000 (0.89–1.14) did not differ from the previously 
published in the literature and was similar among most of the registries around the world. 
Neither the proportion of cyclopias submitted to ETOPFA, nor the numberof births in each 
surveillance program were correlated with the cyclopia prevalence.
An important proportion of cyclopias (31%) was associated with chromosomal anomalies, 
mainly trisomy 13. Another 31% presented with defects that are not related to HPE. This last 
group also had more occurrences of other defects, namely hydrocephalus, heterotaxic 
defects, NTDs, and preaxial reduction defects than the chromosomal group, suggesting the 
presence of ciliopathies or other unrecognized syndromes. The proportion of isolated cases 
(38%) seems inflated, since in 86% of these cases the defect was reported by a single word 
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(i.e., cyclopia), suggesting the practice of naming rather than providing a real description. 
Few non-chromosomal syndromes or associations could be suspected among the MCA 
cases, probably because of the paucity of the clinical descriptions.
The prevalence of all cyclopias by 5-year maternal age groups was higher among mothers in 
the two oldest age groups (35–39 and 40 years old or above), although this finding was not 
statistically significant. There was an expected increased prevalence with maternal age in the 
chromosomal anomaly case group. The prevalence ratio for the older maternal age group, 
relative to the reference age group, was higher and statistically significant in the MCA group 
of cyclopias, suggesting a possible contribution in this group with non-recognized cases of 
trisomies.
The already described excess of females in HPE was seen for the cyclopia casess, in 
livebirths, stillbirths, and in the total sample, without sex differences in the ETOPFA 
sample, MCA, and chromosomal syndrome groups.
Cyclopia differ from other very rare defects by the large contribution of chromosomal 
anomalies to its etiology, underlying the importance of the chromosomal examination, direct 
or through molecular techniques, in isolated or in associated patients. Also etiologically 
important are the nonchromosomal syndromes, making the accurate description of the 
phenotype, including cerebral imaging, and careful collection of familial history essential 
requirements. When possible, molecular studies should be performed since so many genes 
are already associated to this defect. Congenital defects registries around the world must be 
aware of the difficulty of gather this precious material if the verbatim description are the 
result of de-codification. The very rare defects deserve, inside those registries, a special 
treatment, with detailed phenotype descriptions and collection of all possible familial 
information, in order to improve future epidemiological studies.
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BOX 1
Defects Described in Six Cases With Cyclopia
ID Defects Karyotype Diagnoses hypotheses
1 Cyclopia; alobar HPE; microcephaly; external 
hydrocephaly; arhinia;
microstomia; prominent ears; anomalous 
mandible; esophageal atresia;
thoracic hemivertebras; butterfly vertebras; 
anomalous pelvic bone;
preaxial polydactyly; polyhydramnion
46,XX OMIM # 276950 VATER 
with
hydrocephalus
2 Cyclopia; unspecified septal ventricular 
defect; polycystic kidneys adult
type; anomalies of hand (lobster claw hand); 
Arthrogryposis multiplex
congenital
— OMIM 200980
Acrorenal-mandibular
with HPE
3 Cyclopia; microcephalus; jaw defect; 
microtia; preauricular appendage;
microstomia; Meckel diverticulum; radius 
absent
— OMIM % 202650 
Dysgnathia
complex? Ciliopathy?
4 Cyclopia; proboscis above eye; otocephaly; 
micropene; bilateral
criptorquidia; pilonidal pit
— OMIM % 202650 
Dysgnathia
complex
5 Cyclopia, partially fused eyes; proboscis 
above eyes; alobar HPE; arhinia;
microstomia; mouth could not be open; 
microtia; missing first, second
and thirds fingers bilaterally; feet syndactyly 
between second and third
right toes and between third and fourth left 
toes; bilateral agenesis of
radius; anal atresia; ambiguous genitalia; 
pulmonary isomerism;
polisplenia; heart and abdominal organs in the 
midline (situs
ambiguous); ovaries and uterus didelphus; 
one pelvic kidney with two
short ureteres
46,XX OMIM % 202650 
Dysgnathia
complex? Ciliopathy?
6 Cyclopia; alobar HPE; mandible agenesis; 
microtia grade 1; melotia;
preauricular fistula; absent mouth; absent 
tongue; pharyngeal stenosis;
hypoplastic lungs; hypoplastic adrenal glands
46,XX OMIM % 202650 
Dysgnathia
complex
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Figure 1. 
Total prevalence per 100,000 births (bar) and 95% confidence interval (line) by surveillance 
program and overall (dotted line) of cyclopia in 20 surveillance programs members of the 
International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR).
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Figure 2. 
Prevalence ratios for maternal age groups relative to the reference age group of <20 years 
with corresponding 95%CI, for cyclopia in 20 surveillance programs members of the 
International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR).
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